Departments of Chemistry and Molecular Biosciences, Chemistry of Life Processes Institute, Center for Molecular Innovation and Drug Discovery, and Center for Developmental Therapeutics, Northwestern University, Evanston, Illinois 60208, United States.
Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, United States.
ACS Chem Biol. 2021 Apr 16;16(4):615-630. doi: 10.1021/acschembio.0c00784. Epub 2021 Mar 18.
(()-3-Amino-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (OV329) is a recently discovered inactivator of γ-aminobutyric acid aminotransferase (GABA-AT), which has 10 times better inactivation efficiency than its predecessor, CPP-115, despite the only structural difference being an endocyclic double bond in OV329. Both compounds are mechanism-based enzyme inactivators (MBEIs), which inactivate GABA-AT by a similar mechanism. Here, a combination of a variety of computational chemistry tools and experimental methods, including quantum mechanical (QM) calculations, molecular dynamic simulations, progress curve analysis, and deuterium kinetic isotope effect (KIE) experiments, are utilized to comprehensively study the mechanism of inactivation of GABA-AT by CPP-115 and OV329 and account for their experimentally obtained global kinetic parameters and . Our first key finding is that the rate-limiting step of the inactivation mechanism is the deprotonation step, and according to QM calculations and the KIE experiments, accurately represents the enhancement of the rate-limiting step for the given mechanism. Second, the present study shows that the widely used simple QM models do accurately represent the geometric criteria that are present in the enzyme for the deprotonation step. In contrast, QM cluster models successfully represent both the ground state destabilization and the transition state stabilization, as revealed by natural bond orbital analysis. Furthermore, the globally derived values for both of the inactivators represent the inhibitor constants for the initial binding complexes () and indicate the inactivator competition with the substrate according to progress curve analysis and the observed binding isotope effect. The configurational entropy loss accounts for the difference in values between the inactivators. The approach we describe in this work can be employed to determine the validity of globally derived parameters in the process of MBEI optimization for given inactivation mechanisms.
(-3-氨基-(二氟亚甲基)环戊-1-烯-1-羧酸(OV329)是一种最近发现的γ-氨基丁酸氨基转移酶(GABA-AT)失活剂,尽管其唯一的结构差异是 OV329 中环内双键,但其失活效率比其前身 CPP-115 高 10 倍。这两种化合物都是机制性酶失活剂(MBEIs),通过类似的机制使 GABA-AT 失活。在这里,我们结合了多种计算化学工具和实验方法,包括量子力学(QM)计算、分子动力学模拟、进度曲线分析和氘动力学同位素效应(KIE)实验,全面研究了 CPP-115 和 OV329 使 GABA-AT 失活的机制,并解释了它们实验获得的全局动力学参数 和 。我们的第一个关键发现是,失活机制的限速步骤是去质子化步骤,根据 QM 计算和 KIE 实验, 值准确地表示了给定机制中限速步骤的增强。其次,本研究表明,广泛使用的简单 QM 模型 不能准确地表示酶中存在的去质子化步骤的几何标准。相比之下,QM 簇模型成功地代表了基态的去稳定化和过渡态的稳定化,正如自然键轨道分析所揭示的那样。此外,两种失活剂的全局衍生 值 代表了初始结合复合物()的抑制剂常数,并根据进度曲线分析和观察到的结合同位素效应表明了失活剂与底物的竞争。构象熵损失解释了失活剂之间 值差异的原因。我们在这项工作中描述的方法可用于确定在给定失活机制的 MBEI 优化过程中全局衍生参数的有效性。